Caribou Biosciences announces strategic alternatives review, discontinues CAR-T programs, cuts workforce

Caribou Biosciences announced a strategic alternatives review, discontinued its Vispa-Cel and CB-011 CAR-T programs, and cut its workforce. The company had $113.8M in cash at June 30.

Detected & updated continuously · Source: Nebula